Category: Capricor Therapeutics

  • Capricor preps phase 3 for Duchenne cell therapy as it seeks a partner

    Capricor Therapeutics’ bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease progression. Initial results from the 20-patient HOPE-2 trial reported last year showed signs of activity in older boys and young men with advanced DMD, […]